Allergan’s Durysta (bimatoprost implant) Receives the US FDA’s Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

 Allergan’s Durysta (bimatoprost implant) Receives the US FDA’s Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Allergan’s Durysta (bimatoprost implant) Receives the US FDA’s Approval as the First Intracameral Biodegradable Sustained-Release Implant for Patients with OAG and OHT

Shots:

  • The approval is based on two P-III ARTEMIS studies (including 8mos. extended follow up) assessing Durysta (10mcg) vs topical timolol drops (bid) in 1,122 patients with OAG & OHT.
  • The two P-III ARTEMIS studies resulted in a 30% reduction in IOP from baseline in 12wks. primary efficacy period, meeting the predefined criteria for non-inferiority
  •  The approval expands the availability of Allergan’s EyeCue, a reimbursement service for eye care professionals facilitating the patient benefit verification & PA assistance for Allergan Eye Care products. Durysta is a prostaglandin analog, being evaluated in 5 P-III studies that support its FDA label enhancement & ROW approvals

Click here ­to­ read full press release/ article | Ref: Allergan | Image: Allergan

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post